Introduction: Dapagliflozin is a selective
INTRODUCTION
Selective inhibitors of the sodium-glucose cotransporter 2 (SGLT2) [1, 2] are a class of antidiabetic agents with a novel mechanism of action that can be additive and complementary to existing antidiabetic therapies [3] [4] [5] . SGLT2 inhibitors promote urinary glucose excretion in an insulin-independent manner to reduce hyperglycemia and lower glycosylated hemoglobin (HbA 1c ). Additional benefits associated with SGLT2 inhibition include a low risk of hypoglycemia, weight loss due to urinary caloric loss [6] , and diuresis-related blood pressure lowering, with the potential for cardiovascular benefits [7] . SGLT2 inhibition is expected to be a relatively safe approach because SGLT2 is selectively expressed in the kidney [1, 8, 9] . Moreover, the limited data that exist in subjects with familial renal glucosuria due to mutations in the SGLT2 gene indicate that this condition is largely asymptomatic aside from increased glucosuria [10] .
Nonetheless, drugs with novel mechanisms of action require careful examination of potential safety liabilities. In particular, elevated cancer risk is an important concern for patients with type 2 diabetes, since this patient population is already at increased risk of a variety of tumor types [11] [12] [13] .
Dapagliflozin is a small-molecule inhibitor of SGLT2 [3, 4] that has been shown to be highly selective for SGLT2 compared with other SGLT family members and to have no off-target interactions in an in vitro screen of more than 330 receptors, enzymes, ion channels, and transporters [14] . Overall, dapagliflozin demonstrates good oral bioavailability, has a high volume of distribution, and has an in vivo metabolite profile that is qualitatively similar between preclinical species and humans [15] . In humans, the major circulating metabolite is a stable, non-reactive ether glucuronide [dapagliflozin 3-O-glucuronide (D3OG)] that has no pharmacologic activity [15] . It also has no structural alerts for mutagenicity or carcinogenicity nor any off-target effects against a similar broad panel of more than 330 receptors, enzymes, ion channels, and transporters [14] . This glucuronide metabolite is formed at a lower rate in preclinical species but plasma concentrations comparable to or higher than human exposures are achieved at supratherapeutic doses of dapagliflozin used for toxicologic assessments [14] . Non-human species also form a pharmacologically active O-deethylated metabolite, which is only a minor metabolite in humans [15] . Structures for these metabolites are shown in Fig. 1 . All other plasma and urinary dapagliflozin metabolites were formed at relatively low levels in animals and humans and, importantly, the animals assessed in toxicity studies formed them at sufficient levels relative to humans to assess their safety [14, 16] and disease-modifying effects in a variety of animal models of diabetes [3] . In patients with type 2 diabetes mellitus, dapagliflozin treatment achieves significant reductions in HbA 1c , fasting and postprandial glucose, and body weight at the recommended human dose of 10 mg once daily [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Both non-clinical and clinical assessments have shown dapagliflozin to have a highly favorable safety profile that is consistent with its simple mechanism of action, with no off-target effects observed [14] . Despite a balanced overall incidence of malignancies and unspecified tumors between dapagliflozin and control groups (1.5% vs. 1.4%, July 15, 2011 cutoff) [28] , regulatory concern was raised by a small numerical imbalance in urinary bladder tumors in the dapagliflozin global clinical program [9 in the dapagliflozin groups vs. 1 in the placebo groups (incidence rate of 0.15 vs. 0.03)] [29] . This imbalance was not supported by any preclinical data suggestive of a tumor risk [30] .
Thus, we hypothesized that a robust, preclinical carcinogenic risk assessment, including the comprehensive non-clinical toxicity program for dapagliflozin, as well as additional investigative studies assessing whether dapagliflozin or its glucosuria mechanism of action could somehow act as a promoter or growth enhancer of bladder tumors, would help to de-risk any clinical tumor imbalance. The results of these studies and the overall weight of evidence support our conclusion that SGLT2 inhibition in general, and dapagliflozin specifically, are not associated with increased cancer risk.
METHODS
The definitive studies were conducted in compliance with Good Laboratory Practice
Regulations for Nonclinical Laboratory Studies 
Test Articles and Vehicles
tetrahydro-2H-pyran-3,4,5-triol; C21H25ClO6; formula weight *409) and D3OG were synthesized by Bristol-Myers Squibb Company (New Brunswick, NJ, USA). For in vitro studies, dapagliflozin and D3OG metabolite were dissolved in a solution of dimethyl sulfoxide.
In vivo studies were conducted with a propylene glycol solvate of dapagliflozin (dapagliflozin propanediol), which is the form used in humans. The oral dosing vehicle used in the non-clinical toxicity studies consisted of 90% polyethylene glycol (PEG-400; Spectrum Quality Products, New Brunswick, NJ, USA) in 10% water.
In Vitro Genotoxicity Studies
In vitro genotoxicity studies were conducted in accordance with International Conference on Harmonization (ICH) guidelines [31] .
Dapagliflozin was assessed for the potential to induce bacterial mutation in the Ames test in per day over a 2-week period in which plasma exposures were assessed in addition to bone marrow micronuclei formation.
DNA Repair
The effect of dapagliflozin on unscheduled DNA repair was evaluated in groups of ten male SD 
12-Month Dog Study
Beagle dogs were obtained from Marshall Farms 
Investigative Transcriptional Profiling Study
Transcription profiling was performed on RNA samples from a previously conducted efficacy study in which obese male Zucker diabetic fatty (ZDF) rats were dosed orally once daily for 1 or Biotin-labeled cRNAs were generated from the cDNAs and were processed on a Caliper
GeneChip Array Station (Affymetrix). Labeled cRNAs were hybridized on Affymetrix Rat
Genome HT_RG-230PM arrays and processed according to Affymetrix's recommendations. Scanned images were subjected to visual inspection and chip quality reports were generated by Expression console (Affymetrix).
The image data were processed using the Robust Multichip Average method to determine the specific hybridizing signal for each probe set.
The cDNA was synthesized with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems; Foster City, CA, USA).
PCR primers and probe sets were obtained from Applied Biosystems. Ingenuity cDNA that showed a fold change of greater than 1.5 (upward or downward regulation) between treatment and vehicle groups with a P value of less than 0.005 were considered significantly different in relation to treatment. Additionally, transcriptional profiles were compared with published literature of a proposed prognostic genetic signature of tumor promoters [34] .
Statistical significance of the in vivo effects of dapagliflozin on tumor growth were determined using non-parametric statistics by Gehan's generalized Wilcoxon test and required a P value of less than 0.05 [35] .
RESULTS

In Vitro Genotoxicity Studies
Dapagliflozin was negative in the bacterial reverse-mutation assay in S. typhimurium and E. coli strains at maximum concentrations 
Rodent Carcinogenicity Studies
CD-1 Mice
Potential carcinogenicity of orally administered dapagliflozin was assessed in CD-1 mice for a period of up to 24 months as summarized in No. survivors at termination,
26 (43) 24 (40) 26 (43) 18 (30) 20 (33) 28 (47) 21 (35) 19 (32) 22 (37) 25 ( which is a common background lesion in male mice that results in inflammatory changes in urogenital tissues (including male accessory sex glands such as prostate and seminal vesicles) and partial to full urogenital obstruction, often presenting as urinary bladder dilatation lymphoreticular system, uterus and cervix, lung, and liver were observed in the water and vehicle control groups. Dapagliflozin did not increase the incidence of these background tumors or shorten the time to onset. Importantly, there were no indications of any tumors in the urogenital tract or urinary bladder despite some background hyperplastic effects in the bladder of male mice. Dapagliflozin did not increase urinary bladder hyperplasia over that observed in control male mice (Fig. 2) .
Moreover, no difference was observed in the kidney between control and dapagliflozintreated mice, except for the aforementioned increased incidence of dilated renal pelves.
SD Rats
Similar carcinogenicity studies were conducted in SD rats for a period of up to 24 months as summarized in Table 2 . Female rats were and in rats treated with control or dapagliflozin 10 mg/kg per day for 90 weeks. a Bladder displaying incidental hyperplasia in dapagliflozin-treated (left) and control (right) male mice. In both cases, there is moderate hyperplasia of the transitional cell urothelial lining of the urinary bladder, characterized by thickening of the urothelium with an increased number of uniform cells retaining the differentiated and relatively organized character of regular epithelium, with no cellular atypia. The apparent variation in thickness is partially due to folding and/or tangential sectioning. The incidental hyperplasia is secondary to inflammation/infection, often related to mouse urologic syndrome. b Urinary bladder in dapagliflozin-treated (left) and control (right) male rats. In both cases, the transitional cell urothelial lining of the urinary bladder appears normal and relatively thin. 9100 magnification Table 2 Summary of 24-month oral carcinogenicity study with dapagliflozin in rats No. survivors at termination, n (%) 20 (29) 22 (31) 31 (44) 30 (43) 22 (31) 28 (40) 33 (47) 31 (44) 25 (36) 27 ( Percentage of deaths attributed to a specific cause terminated as planned at weeks 105-106. Due to declining survival in males in the two control groups and the 10 mg/kg per day group, males in all groups were terminated at weeks 89-91 to ensure sufficient numbers of rats for statistical analysis. In males, the most common cause of death was chronic progressive nephropathy (CPN), a common background finding in SD rats [37] . The higher incidence of death at 10 mg/kg per day in males was attributable to a dapagliflozin-related increase in severity of this commonly observed background condition (Fig. 3) .
Dapagliflozin was not carcinogenic in rats at doses up to 10 mg/kg per day. There was a low incidence of pituitary tumors in the male rats, but the incidence of these tumors did not increase in the dapagliflozin groups. In female rats, the most common causes of death were benign and malignant mammary and pituitary tumors, but there was no dapagliflozin-related increase in the incidences or in the time to and kidney pathology in rats treated with control or dapagliflozin 10 mg/kg per day for 90 weeks. a Kidney in dapagliflozin-treated (left) male mice and control (right). In both cases, the kidney cortex appears similar and shows normal glomeruli and renal cortical tubules. b Chronic progressive nephropathy (CPN) in control (left, moderate) and dapagliflozin-treated (right, severe) rats. The CPN is characterized by multifocal dilated tubules often filled with proteinaceous fluid, tubules with cytoplasmic basophilia and focally thickened tubular basement membranes, and foci of increased mononuclear cell infiltrates in the interstitium. There was exacerbation of CPN (increased severity) in the dapagliflozin-treated male rats (i.e., higher incidence of severe CPN in the dapagliflozin-treated males vs. controls). 9100 magnification onset of these tumors. Importantly, there were no indications of any dapagliflozin-related tumors or preneoplastic lesions in the urinary bladder (Fig. 2) in rats. There were also no dapagliflozin-related neoplasms affecting the renal tubules, adrenal gland, or testicular Leydig cells as has been reported by the US Food and Drug Administration for canagliflozin [38] . In males only, there were microscopic changes in the kidney, which included exacerbation in severity of CPN and increased incidence and severity of minimal to marked atypical hyperplasia of renal cortical tubules. 
Additional Supportive Animal Studies
Dog Toxicology Studies
Urinary Exposure Extrapolations
Our previous report indicated that systemic (i.e., plasma AUCs) exposures to dapagliflozin and its primary human metabolite, D3OG, in animal toxicity and carcinogenicity studies were at least equal to and often far exceeded human exposures at the MRHD [14] . Microscopic evaluation of the urinary bladder, kidneys, liver, heart, pancreas, adrenal glands, thyroids, spleen, female reproductive tract, male sex glands, skin, brain, and skull did not reveal any adverse effect attributable to SGLT2 gene deletion. Of particular note, no hyperplasia or neoplasia was observed in the urinary bladder mucosa (Fig. 4) , urogenital tract, or kidneys. One SGLT2 KO male had polycystic kidney disease, a known spontaneous background condition in C57BL/6J mice [40] , and, therefore, not attributable to SGLT2 gene deletion. Histopathology of this animal was consistent with this condition.
Assessment of Tumor Promotion and Tumor Growth Enhancement
Transcriptional Profiling
In an attempt to evaluate whether dapagliflozin [42] .
Assessment of Tumor Growth Enhancement
In Vivo Dapagliflozin (Fig. 5) at exposures up to 759 human clinical exposures also had no effect on 
DISCUSSION
This article provides a comprehensive preclinical evaluation of the potential carcinogenic risk for selective SGLT2 inhibition and specifically for the first drug in this new therapeutic class to reach the marketplace, dapagliflozin. While the authors acknowledge that these data cannot definitively prove the absence of any carcinogenic risk, they provide very strong weight of evidence that selective SGLT2 inhibition in general, and dapagliflozin specifically, do not present a risk for initiating, promoting, or enhancing malignancies.
Structure-activity analyses, a variety of genotoxicity assessments, and 2-year rodent carcinogenicity assays with dapagliflozin at exposures that far exceeded clinical relevance, were all negative, indicating that neither dapagliflozin nor its metabolites are tumorinitiating carcinogens. There was also no decrease in time to onset or overall increase in the incidence of common background tumor types (e.g., mammary tumors in rats) suggesting that dapagliflozin does not promote tumor growth. Furthermore, no evidence was observed of dapagliflozin-related proliferative or hyperplastic effects (i.e., neoplastic precursors) in the urinary bladder in the rodent carcinogenicity studies at [1009 MRHD exposures. Although no neoplasms were observed in the kidney, there was an increase in the incidence and severity of atypical hyperplasia in the cortical tubules of male rats. As atypical hyperplasia of renal tubules is a common sequel to advanced CPN, the increased atypical hyperplasia was considered a direct result of the increased severity of CPN in these animals. While CPNassociated hyperplastic renal tubular epithelium is a potential precursor of renal tubular epithelial tumors in rats, such tumors were not observed in the current study and they are not considered a predictor of renal tumors in humans [43] . Of note, since the SGLT2 inhibitor phlorizin is pharmacologically active in the renal cortex of rats with experimental diabetes, it is also likely that dapagliflozin retains its pharmacological activity in the hyperplastic renal tubular epithelium of rats with CPN [44] . Dapagliflozin did not bind to hormone receptors in secondary pharmacology screens nor did it induce changes in repeat-dose rat toxicity studies that would be consistent with hormonal perturbation (e.g., no microscopic changes in any sex organs, and no changes in onset of puberty, estrous cycling, or fertility) [14] . There was also no evidence of immunotoxicologic effects in repeat-dose toxicity studies conducted with dapagliflozin (e.g., no changes in lymphoid tissue or hematology parameters).
The lack of carcinogenicity findings is further supported by chronic toxicity studies conducted in rats and dogs that similarly showed no carcinogenicity [14] . The lack of dapagliflozin-related proliferative/hyperplastic changes in the 12-month toxicity study conducted in dogs at [3,0009 MRHD exposures is noteworthy as dogs are particularly sensitive to bladder carcinogenesis [39] . Although the effects observed in the rodent and dog bioassays are not a guaranteed predictor of a lack of a cancer risk for humans, the complete absence of any effects or risk factors in these and other assays provides strong evidence for the absence of a true cancer risk of dapagliflozin to humans.
The observed reduction in overall survival in male mice receiving 15 and 40 mg/kg per day dapagliflozin is most likely related to the diuretic effects of dapagliflozin in mice and not to any potential increased risk for cancer.
The early deaths observed in these animals were attributable to exacerbation of MUS, a spontaneous, mouse-specific background condition commonly seen in untreated male CD-1 mice that leads to urogenital obstruction and mortality [36] . MUS was observed in CD-1 mice but not in SGLT2 -/-mice likely due to differences among strain [46] [47] [48] , age, and housing conditions. For example, CD-1 mice are inherently more susceptible to MUS, were older than the SGLT2 -/-mice, and were housed in wire-bottom cages, which have been shown to exacerbate incidence and severity of MUS [46] . Similarly, the increased mortality in male rats observed with dapagliflozin was due to an exacerbation of CPN. CPN is also a common spontaneous lesion that has no counterpart in humans and has recently been discussed as being of little relevance to human risk assessment [49] . The non-neoplastic findings in mice and rats were not associated with other microscopic changes and were likely adaptive responses to increased urine volume secondary to osmotic diuresis due to increases in urinary glucose excretion. Similar changes in the kidney and urinary bladder of male mice and rats have also been reported in 24-month carcinogenicity studies with the diuretic furosemide [50] , which were also not associated with any tumorigenic risks. Given that both MUS and rat CPN are species specific and without a counterpart in humans, these data showed no increased risk that would be relevant to humans. The entirety of the preclinical toxicology study program was also noteworthy in terms of appropriateness for testing of on-and off-target effects from dapagliflozin or its metabolites.
Dapagliflozin is pharmacologically active in all of the preclinical animal species used and the exposures in animals were in such excess of human exposures that the potential for offtarget effects could be reliably tested. Moreover, the metabolic profile across species is qualitatively similar, with no unique human metabolites, and, when one considers the high doses tested in toxicology studies, is quantitatively suitable for safety evaluation of all metabolites.
The absence of any non-clinical evidence for tumor risk is consistent with results from the clinical program, in which the dapagliflozin and control groups were balanced for the overall occurrence of malignant and unspecified tumors [28, 29] . As would be expected for a drug that does not cause malignancy, the incidence rate for tumors was lower in the comparator group in some organ systems and lower in the dapagliflozin group in others, leading to the overall balance in total malignancies. However, there was a numerical imbalance in bladder cancer cases Consistent with the literature, the current study also found no evidence that elevated glucose levels stimulated cell proliferation as characterized by hyperplastic changes that are requisite for tumor promotion [51] . No evidence of dapagliflozin-related proliferative or hyperplastic effects in the bladder was observed throughout the toxicology program, in which glucosuria was a consistent finding [14] . High levels of urinary glucose on the order of 200 mM in the 2-year rodent carcinogenicity studies and up to 400-500 mM in the chronic toxicology studies, which correspond well to those observed in human subjects (mean of 166 mM at a 10 mg dose) [21] , did not lead to bladder tumor development, even in male mice in which background bladder hyperplasia was observed.
Additionally, an analysis of
15-month-old SGLT2
-/-mice that had experienced a lifetime of glucosuria failed to reveal evidence of proliferative, hyperplastic, or preneoplastic type changes. If glucosuria stimulated or promoted tumor proliferation, these environments would likely have led to progression from hyperplasia to preneoplastic lesions.
Having found no evidence that dapagliflozin or glucosuria exert hyperplastic or tumorogenic effects, we explored the possibility that glucose itself, dapagliflozin, or its primary human metabolite could enhance or accelerate growth of bladder tumor cells. We used an experimental strategy similar to the one that was used to analyze the antithrombotic drug prasugrel [52] . Prasugrel also led to numerical imbalances in specific tumor types during phase therefore any on-target effects would be expected to occur in the kidney [8, 9] .
Moreover, dapagliflozin is highly selective for SGLT2, which makes off-target effects unlikely [6, 14] . To date, there is no published report of cancer risk associated with selective SGLT2 inhibition. To the contrary, some published data suggest that inhibition of SGLT2 may actually decrease growth in tumor cells expressing this transporter by inhibiting glucose uptake into the malignant cells [53, 54] . In vitro data from this study have shown that supraphysiologic urinary glucose concentrations above 20 mM, which is still well below the levels caused by dapagliflozin in the clinic (166 mM) and in animal studies (up to 400-500 mM) [14, 21] , actually inhibited tumor cell growth of a variety of human bladder TCC tumor cell lines.
Recently, carcinogenicity results for canagliflozin, an SGLT2 inhibitor that, compared with dapagliflozin, is less selective for SGLT2 than for SGLT1 (canagliflozin, 2009; dapagliflozin, 1,2009) [55] , were publically disclosed [38] . Canagliflozin did not increase the incidence of neoplasms or preneoplastic lesions in CD-1 mice in a 2-year carcinogenicity study at exposures 149 clinical exposures [38] . In rats, canagliflozin increased the incidence of neoplasms of the renal tubules (C129), adrenals (C129), and testicular Leydig cells of SD rats (C19). These events have been hypothesized to be related to carbohydrate malabsorption and calcium imbalance due to SGLT1 inhibition, which may explain why similar tumors were not observed with dapagliflozin. In neither rodent species was there any evidence of an increased risk of bladder tumors. Publically disclosed clinical results for canagliflozin also did not suggest any malignancy signal (with 8,000
person-years exposure), further supporting the safety of SGLT2 inhibition in humans [38] .
CONCLUSION
The studies presented here were undertaken because it is well recognized that even the most extensive clinical development programs can at 
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